The historical rank and industry rank for Amphastar Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:
AMPH's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.26 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Amphastar Pharmaceuticals 5-Year Yield-on-Cost % Related Terms
AMPH vs ETON, PCRX, BIOA: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amphastar Pharmaceuticals 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Amphastar Pharmaceuticals's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Amphastar Pharmaceuticals (AMPH) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 05, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Amphastar Pharmaceuticals and its competitors. According to the industry distribution chart, Amphastar Pharmaceuticals ranks #999999 out of 517 companies in the Drug Manufacturers industry.
Is Amphastar Pharmaceuticals' 5-Year Yield-on-Cost % too high?
Amphastar Pharmaceuticals' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Amphastar Pharmaceuticals ranks #999999 out of 517 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Amphastar Pharmaceuticals has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amphastar Pharmaceuticals' 5-Year Yield-on-Cost % compare to ETON and PCRX?
According to the Drug Manufacturers industry distribution chart, Amphastar Pharmaceuticals ranks #999999 out of 517 companies for 5-Year Yield-on-Cost %. This places Amphastar Pharmaceuticals in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.26, based on 517 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Amphastar Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amphastar Pharmaceuticals's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amphastar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals (AMPH) is currently considered Significantly Undervalued. The stock's GF Value™ is $48.81, compared to a current price of $19.66 — trading 59.7% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Amphastar Pharmaceuticals' overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Amphastar Pharmaceuticals (AMPH), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amphastar Pharmaceuticals (AMPH) Overvalued in 2026?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued.
The current stock price of $19.66 is trading 59.7% below its estimated GF Value™ of $48.81.
GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for AMPH:
5-Year Yield-on-Cost %: 0.00
GF Value™: $48.81 vs. price of $19.66 (59.7% below fair value)
No single metric tells the full story. See the AMPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
83GF Score
Get the complete analysis for AMPH
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMPH has been successfully added to your 